Cargando…
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances in drug research and development (R & D) for...
Autores principales: | Caridha, Diana, Vesely, Brian, van Bocxlaer, Katrien, Arana, Byron, Mowbray, Charles E., Rafati, Sima, Uliana, Silvia, Reguera, Rosa, Kreishman-Deitrick, Mara, Sciotti, Richard, Buffet, Pierre, Croft, Simon L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904839/ https://www.ncbi.nlm.nih.gov/pubmed/31320296 http://dx.doi.org/10.1016/j.ijpddr.2019.06.003 |
Ejemplares similares
-
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
por: Van Bocxlaer, Katrien, et al.
Publicado: (2019) -
Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019) -
In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis
por: Sengupta, Ritika, et al.
Publicado: (2019) -
Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
por: Sousa-Batista, Ariane J., et al.
Publicado: (2019) -
Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis
por: Goyonlo, Vahid Mashayekhi, et al.
Publicado: (2019)